Pharmedic Pharmaceutical Medicinal JSC (HNX:PMC)
Vietnam
· Delayed Price · Currency is VND 142,000
-13,000 (-8.39%)
At close: Mar 6, 2026
HNX:PMC Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 546,567 | 498,185 | 485,186 | 472,274 | 414,232 | Upgrade
|
| Revenue Growth (YoY) | 9.71% | 2.68% | 2.73% | 14.01% | -10.10% | Upgrade
|
| Cost of Revenue | 323,367 | 310,972 | 315,134 | 285,918 | 266,740 | Upgrade
|
| Gross Profit | 223,200 | 187,213 | 170,053 | 186,356 | 147,492 | Upgrade
|
| Selling, General & Admin | 121,120 | 96,729 | 85,645 | 95,588 | 74,912 | Upgrade
|
| Other Operating Expenses | 4,180 | - | - | - | - | Upgrade
|
| Operating Expenses | 125,300 | 96,729 | 85,645 | 95,588 | 74,912 | Upgrade
|
| Operating Income | 97,900 | 90,484 | 84,408 | 90,768 | 72,580 | Upgrade
|
| Interest Expense | -302.47 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 3,852 | 9,557 | 19,853 | 13,178 | 9,363 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.28 | 2.37 | 17.19 | -43.02 | 27.29 | Upgrade
|
| Other Non Operating Income (Expenses) | 452.42 | 269.41 | 148.96 | -675.76 | -1,022 | Upgrade
|
| EBT Excluding Unusual Items | 101,903 | 100,313 | 104,427 | 103,227 | 80,949 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1,202 | - | 175.45 | 1,253 | 334.97 | Upgrade
|
| Other Unusual Items | -105.17 | - | - | - | - | Upgrade
|
| Pretax Income | 102,999 | 100,313 | 104,602 | 104,480 | 81,284 | Upgrade
|
| Income Tax Expense | 20,695 | 20,180 | 21,038 | 21,064 | 16,524 | Upgrade
|
| Net Income | 82,305 | 80,133 | 83,564 | 83,416 | 64,760 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 21,636 | 22,562 | 22,522 | 17,485 | Upgrade
|
| Net Income to Common | 82,305 | 58,497 | 61,002 | 60,894 | 47,275 | Upgrade
|
| Net Income Growth | 2.71% | -4.11% | 0.18% | 28.81% | -13.21% | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| EPS (Basic) | 8819.10 | 6268.07 | 6536.47 | 6524.89 | 5065.55 | Upgrade
|
| EPS (Diluted) | 8819.10 | 6268.00 | 6536.00 | 6524.89 | 5065.55 | Upgrade
|
| EPS Growth | 40.70% | -4.10% | 0.17% | 28.81% | -13.21% | Upgrade
|
| Free Cash Flow | -58,932 | 39,227 | 86,678 | 31,675 | 58,885 | Upgrade
|
| Free Cash Flow Per Share | -6314.62 | 4203.23 | 9287.65 | 3394.02 | 6309.63 | Upgrade
|
| Dividend Per Share | - | 2400.000 | 19100.000 | 3000.000 | 2400.000 | Upgrade
|
| Dividend Growth | - | -87.44% | 536.67% | 25.00% | - | Upgrade
|
| Gross Margin | 40.84% | 37.58% | 35.05% | 39.46% | 35.61% | Upgrade
|
| Operating Margin | 17.91% | 18.16% | 17.40% | 19.22% | 17.52% | Upgrade
|
| Profit Margin | 15.06% | 11.74% | 12.57% | 12.89% | 11.41% | Upgrade
|
| Free Cash Flow Margin | -10.78% | 7.87% | 17.87% | 6.71% | 14.21% | Upgrade
|
| EBITDA | 109,758 | 101,755 | 96,345 | 103,311 | 86,549 | Upgrade
|
| EBITDA Margin | 20.08% | 20.42% | 19.86% | 21.88% | 20.89% | Upgrade
|
| D&A For EBITDA | 11,858 | 11,271 | 11,938 | 12,543 | 13,968 | Upgrade
|
| EBIT | 97,900 | 90,484 | 84,408 | 90,768 | 72,580 | Upgrade
|
| EBIT Margin | 17.91% | 18.16% | 17.40% | 19.22% | 17.52% | Upgrade
|
| Effective Tax Rate | 20.09% | 20.12% | 20.11% | 20.16% | 20.33% | Upgrade
|
| Revenue as Reported | 546,567 | 498,185 | 485,186 | 472,274 | 414,232 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.